Construction projects on campus

In recent years, four new research buildings have been erected on the science and biotech campus, including the Käthe-Beutler-Haus of the Berlin Institute of Health. The expansion of the technology platforms began with the new building for cryo-electron microscopy, and a building for state-of-the-art NMR is currently under construction. In addition, an Optical Imaging Center is planned.
Construction is also underway in the BiotechPark, where a new life science start-up center, the "BerlinBioCube," will be built by 2023.
These developments follow an urban design and landscape planning framework concept with the forward-looking guiding principle of a "Green Health Campus". Sustainability is a crucial component in living up to the claim of being a leading science and business location in the Berlin-Brandenburg capital region.
Figure: Entwurf der sinai - Gesellschaft von Landschaftsarchitekten mbH
BerlinBioCube - Start-up Center

Campus Berlin-Buch GmbH (CBB) is building the new life science start-up center BerlinBioCube on the Berlin-Buch campus from 2020. The CBB operates and develops the research and biotech campus in Berlin-Buch, which focuses on biomedicine. The spectrum of the BiotechPark Berlin-Buch includes medical biotechnology, medical technology and related areas. In the BerlinBioCube, more jobs can now be created in innovative areas of the healthcare industry.
Construction began in August 2020 and the topping-out ceremony took place in October 2021. The BerlinBioCube will offer a total of 8,000 square meters of space on five floors for modern laboratories, offices, communal areas for daily encounters and exchange as well as conference rooms. Young start-ups can move into the new BiotechPark Berlin-Buch building as early as 2023 and benefit from the very good conditions that the campus offers. The building was designed by the architecture office doranth post architects, Munich. The new building of the BerlinBioCube involves an investment of 55 million euros, of which around 40 percent will go into the technical equipment. The financing is made possible by funds from the joint task "Improvement of the regional economic structure" (GRW).
With 65 companies, 820 employees and around 31,000 square meters of office and laboratory space, the BiotechPark Berlin-Buch is one of the leading technology parks in Germany. Spin-offs in the life sciences sector will find ideal conditions here, from technology transfer to industry-specific laboratory and office space. The local life science community enables direct exchange and joint projects. The BiotechPark makes a major contribution to the dynamic development of the Berlin-Brandenburg biotechnology region and particularly strengthens the industrial health economy.
Fig.: doranth post architects
www.berlinbiocube.de
Building for NMR III

On the eastern edge of the campus, NMR-III, a further building for nuclear magnetic resonance (NMR) spectroscopy of the Leibniz Research Institute for Molecular Pharmacology (FMP), is currently under construction. The building will house the new 1.2GHz NMR spectrometer, which is scheduled for delivery in the fall of 2022 and will include the strongest magnet (with a magnetic field of 28.2 Tesla) that can currently be used for NMR. Because of its higher sensitivity and better resolution, the instrument will greatly enhance the ability to apply NMR to the determination of the structure and dynamics of biomolecules at the FMP. Construction began in October 2021 and is expected to be completed in the summer of 2022. The device and the building are jointly financed through a special application to the Leibniz Association, with the federal government and the state of Berlin each contributing half of the total cost of 13.5 million euros.
Figure/Draft: DGI Bauwerk Gesellschaft von Architekten mbH
News Buch Berlin
Starting up with highly promising immunotherapies
After spending many years researching together, a group of scientists has founded CARTemis Therapeutics, a spin-off from the Max Delbrück Center. Uta Höpken, Armin Rehm, Anthea Wirges, and Mario Bunse...
more ...OMEICOS Therapeutics Provides Update on PMD-OPTION Phase 2a Clinical Study Evaluating OMT-28 in Primary Mitochondrial Disease
OMEICOS, a biopharmaceutical company developing first-in-class small molecule therapeutics based on the profound understanding of omega-3 fatty acid metabolism and physiology, today provided a positiv...
more ...The thrill of science
Young students are fascinated by the experiments they can participate in at the Gläsernes Labor (Life Science Learning Lab). Thanks to a special fundraiser, socially disadvantaged children from the di...
more ...Events Buch Berlin
09.10.2023, 09:00
Explore Precision Medicine Event im Futurium
Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.
more ...